Published in Ann N Y Acad Sci on June 01, 2007
Response to rituximab in a case of lupus associated digital ischemia. Case Rep Rheumatol (2014) 0.75
Digital gangrene as the initial presentation of systemic lupus erythematosus. BMJ Case Rep (2012) 0.75
Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum (2002) 5.12
International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. Ann Rheum Dis (2013) 3.99
Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum (2002) 3.96
A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum (2011) 3.81
Human papilloma virus vaccine and primary ovarian failure: another facet of the autoimmune/inflammatory syndrome induced by adjuvants. Am J Reprod Immunol (2013) 3.42
Pathogenesis and natural history of osteonecrosis. Semin Arthritis Rheum (2002) 3.30
Autoantibody explosion in systemic lupus erythematosus: more than 100 different antibodies found in SLE patients. Semin Arthritis Rheum (2004) 3.23
Vitamin D effects on musculoskeletal health, immunity, autoimmunity, cardiovascular disease, cancer, fertility, pregnancy, dementia and mortality-a review of recent evidence. Autoimmun Rev (2013) 2.87
HIV and autoimmunity. Autoimmun Rev (2002) 2.83
Vitamin D and autoimmunity: new aetiological and therapeutic considerations. Ann Rheum Dis (2007) 2.76
Measurement of electrical skin impedance of dermal-visceral zones as a diagnostic tool for inner organ pathologies: a blinded preliminary evaluation of a new technique. Isr Med Assoc J (2005) 2.57
Effects of tobacco smoke on immunity, inflammation and autoimmunity. J Autoimmun (2009) 2.49
Vitamin D and musculoskeletal health, cardiovascular disease, autoimmunity and cancer: Recommendations for clinical practice. Autoimmun Rev (2010) 2.38
Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials. Arthritis Rheum (2013) 2.25
Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis (2012) 2.21
Vascular involvement in Behçet's disease: relation with thrombophilic factors, coagulation activation, and thrombomodulin. Am J Med (2002) 2.17
Vaccination may be associated with autoimmune diseases. Isr Med Assoc J (2004) 2.14
Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials. Ann Rheum Dis (2013) 2.11
Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. Ann Rheum Dis (2010) 2.09
The Lancet against Israel. Isr Med Assoc J (2013) 2.03
Intensive lipid-lowering therapy: obvious benefits, possible risks. Isr Med Assoc J (2006) 2.02
Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial. Arthritis Rheum (2004) 1.89
The role of inflammatory cytokines in the pathogenesis of systemic lupus erythematosus-related atherosclerosis: a novel target for treatment? J Rheumatol (2006) 1.79
Catastrophic antiphospholipid syndrome: where do we stand? Arthritis Rheum (2003) 1.79
Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of a series of 280 patients from the "CAPS Registry". J Autoimmun (2009) 1.78
Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis Res Ther (2006) 1.78
Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXIII. Baseline predictors of vascular events. Arthritis Rheum (2004) 1.75
Association between vaccination and Guillain-Barré syndrome. Lancet Infect Dis (2013) 1.69
Vitamin D insufficiency in a sunny environment: a demographic and seasonal analysis. Isr Med Assoc J (2010) 1.68
Defining and analyzing geoepidemiology and human autoimmunity. J Autoimmun (2010) 1.67
Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann Rheum Dis (2012) 1.67
Matrix metalloproteinase-9 and autoimmune diseases. J Clin Immunol (2006) 1.66
Intravenous immunoglobulin therapy affects T regulatory cells by increasing their suppressive function. J Immunol (2007) 1.64
Assessment of subclinical vascular disease associated with ankylosing spondylitis. J Rheumatol (2011) 1.62
Adrenal involvement in the antiphospholipid syndrome: clinical and immunologic characteristics of 86 patients. Medicine (Baltimore) (2003) 1.58
The geoepidemiology of systemic lupus erythematosus. Autoimmun Rev (2009) 1.57
The antiphospholipid syndrome as a neurological disease. Semin Arthritis Rheum (2009) 1.57
The hyperferritinemic syndrome: macrophage activation syndrome, Still's disease, septic shock and catastrophic antiphospholipid syndrome. BMC Med (2013) 1.56
Helicobacter pylori serology in autoimmune diseases - fact or fiction? Clin Chem Lab Med (2013) 1.56
The role of CD40-CD154 interactions in autoimmunity and the benefit of disrupting this pathway. Autoimmunity (2004) 1.54
Gender and autoimmunity. Autoimmun Rev (2006) 1.54
Erdheim-Chester Disease: a comprehensive review of the literature. Orphanet J Rare Dis (2013) 1.54
Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors in a series of 250 patients. Arthritis Rheum (2006) 1.53
Vascular involvement in Behçet's disease. Isr Med Assoc J (2002) 1.53
Hydroxychloroquine: from malaria to autoimmunity. Clin Rev Allergy Immunol (2012) 1.53
Intravenous immunoglobulin: adverse effects and safe administration. Clin Rev Allergy Immunol (2005) 1.52
Inflammatory bowel disease: adverse effect of isotretinoin. Isr Med Assoc J (2009) 1.51
Mechanisms of disease: atherosclerosis in autoimmune diseases. Nat Clin Pract Rheumatol (2006) 1.46
Sarcoidosis in patients with chronic hepatitis C virus infection: analysis of 68 cases. Medicine (Baltimore) (2005) 1.46
Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis (2014) 1.45
Preventing death in the catastrophic antiphospholipid (Asherson) syndrome. Isr Med Assoc J (2007) 1.44
Thymoma and autoimmunity. Cell Mol Immunol (2011) 1.44
Novel aspects of Sjögren's syndrome in 2012. BMC Med (2013) 1.44
Triple association between hepatitis C virus infection, systemic autoimmune diseases, and B cell lymphoma. J Rheumatol (2004) 1.44
IL-2 receptor alpha deficiency and features of primary biliary cirrhosis. J Autoimmun (2006) 1.43
Efficacy of cyclophospamide in the treatment of interstitial lung disease associated with systemic sclerosis. Arch Bronconeumol (2011) 1.42
Intelligent nutrition: health-promoting mechanisms of probiotics. Isr Med Assoc J (2003) 1.42
Antiphospholipid syndrome in Mexican children. Isr Med Assoc J (2012) 1.39
Safety of intravenous immunoglobulin (IVIG) therapy. Autoimmun Rev (2006) 1.39
Systemic thromboembolism in inflammatory bowel disease: mechanisms and clinical applications. Ann N Y Acad Sci (2005) 1.39
Hippocrates' Oath is challenged. Isr Med Assoc J (2009) 1.38
Infections and SLE. Autoimmunity (2005) 1.38
Primary Sjögren syndrome: clinical and immunologic disease patterns in a cohort of 400 patients. Medicine (Baltimore) (2002) 1.37
CD4+CD28- T lymphocytes contribute to early atherosclerotic damage in rheumatoid arthritis patients. Circulation (2004) 1.36
Accelerated atherosclerosis in rheumatoid arthritis. Ann N Y Acad Sci (2007) 1.36
Infection, vaccines and other environmental triggers of autoimmunity. Autoimmunity (2005) 1.36
Lupus nephritis: a critical review. Autoimmun Rev (2012) 1.36
Schizophrenia, autoimmunity and immune system dysregulation: a comprehensive model updated and revisited. J Autoimmun (2006) 1.35
Parotitis as the presenting symptom of Wegener's granulomatosis: case report and meta-analysis. Isr Med Assoc J (2013) 1.35
What is the contents of the magic draft IVIg? Autoimmun Rev (2008) 1.31
Neuropsychiatric syndromes in systemic lupus erythematosus: a meta-analysis. Semin Arthritis Rheum (2010) 1.31
Infections and autoimmunity--friends or foes? Trends Immunol (2009) 1.31
Endothelial dysfunction and atherosclerosis in rheumatoid arthritis: a multiparametric analysis using imaging techniques and laboratory markers of inflammation and autoimmunity. J Rheumatol (2008) 1.29
Pathogenesis of infertility and recurrent pregnancy loss in thyroid autoimmunity. J Autoimmun (2012) 1.28
Vitamin D and autoimmune thyroid diseases. Cell Mol Immunol (2011) 1.28
Autoantibodies involved in neuropsychiatric SLE and antiphospholipid syndrome. Semin Arthritis Rheum (2007) 1.27
A novel automated indirect immunofluorescence autoantibody evaluation. Clin Rheumatol (2011) 1.27
The autoimmune bases of infertility and pregnancy loss. J Autoimmun (2012) 1.27
Novel biomarkers in autoimmune diseases: prolactin, ferritin, vitamin D, and TPA levels in autoimmune diseases. Ann N Y Acad Sci (2007) 1.26
Precocious intima-media thickening in patients with primary Sjögren's syndrome. Arthritis Rheum (2005) 1.25
Sjögren's syndrome, the old and the new. Best Pract Res Clin Rheumatol (2012) 1.25
Practical guidelines for the supplementation of vitamin D and the treatment of deficits in Central Europe - recommended vitamin D intakes in the general population and groups at risk of vitamin D deficiency. Endokrynol Pol (2013) 1.25
Validated methods for assessment of subclinical atherosclerosis in rheumatology. Nat Rev Rheumatol (2012) 1.23
Vitamin D in systemic and organ-specific autoimmune diseases. Clin Rev Allergy Immunol (2013) 1.23
Protective molecules--C-reactive protein (CRP), serum amyloid P (SAP), pentraxin3 (PTX3), mannose-binding lectin (MBL), and apolipoprotein A1 (Apo A1), and their autoantibodies: prevalence and clinical significance in autoimmunity. J Clin Immunol (2005) 1.23
Biologic therapy for autoimmune diseases: an update. BMC Med (2013) 1.23
Surviving the butterfly and the wolf: mortality trends in systemic lupus erythematosus. Autoimmun Rev (2004) 1.22
Pediatric antiphospholipid syndrome: clinical and immunologic features of 121 patients in an international registry. Pediatrics (2008) 1.20
Bacterial induction of autoantibodies to beta2-glycoprotein-I accounts for the infectious etiology of antiphospholipid syndrome. J Clin Invest (2002) 1.19
Induction of autoimmune depression in mice by anti-ribosomal P antibodies via the limbic system. Arthritis Rheum (2007) 1.19
Hepatitis B virus (HBV) and autoimmune disease. Clin Rev Allergy Immunol (2008) 1.19
Autoimmune/inflammatory syndrome induced by adjuvants (ASIA) 2013: Unveiling the pathogenic, clinical and diagnostic aspects. J Autoimmun (2013) 1.19
Juvenile idiopathic arthritis. Autoimmun Rev (2005) 1.18
Are anti-ribosomal P protein antibodies relevant in systemic lupus erythematosus? Clin Rev Allergy Immunol (2007) 1.18
Vasculitis in systemic lupus erythematosus: prevalence and clinical characteristics in 670 patients. Medicine (Baltimore) (2006) 1.18
SLE and infections. Clin Rev Allergy Immunol (2003) 1.17
The idiotypic network in autoimmunity: antibodies that bind antibodies that bind antibodies. Nat Med (2004) 1.17
The infectious etiology of vasculitis. Autoimmunity (2009) 1.16